

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No 05-980-F; (EX03-067C-US))**

In the Application of:)	
)	
Francis-Lang <i>et al.</i>)	
)	Examiner: Berttoglio, Valarie
Serial No.: 10/528,021)	
)	Group Art Unit: 1632
Filing Date: July 29, 2005)	
)	Confirmation No. 1018
For: PAKs as Modifiers of the CHK)	
Pathway and Methods of Use)	

RESPONSE TO RESTRICTION REQUIRMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on August 8, 2007, in the above-mentioned application. Applicants submit herewith a petition for a five month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group III, drawn to an in vitro method of identifying a candidate CHK pathway modulating agent comprising providing an assay system wherein the assay system is a cell proliferation assay system, for prosecution on the merits. The claims readable thereon are claims 1-4, 6, and 16-17.

If the Examiner has any questions regarding this response, she is invited to call the undersigned attorney.

Respectfully submitted,

Dated: February 8, 2008

/Anita J. Terpstra/
Anita J. Terpstra, Ph.D.
Registration No. 47,132

McDonnell, Boehnen,
Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001